Results 171 to 180 of about 395,113 (303)

Clinical Features and Outcomes of Locally Advanced and Metastatic Basal Cell Carcinoma. [PDF]

Acta Derm Venereol
Zwanenburg AAJH, Van Houdt WJ, Schrijver AM, Schreuder WH, Wouters MWJM, Plasmeijer EI.   +5 more
europepmc   +1 more source

Metastatic basal cell carcinoma: A clinicopathologic study of seventeen cases

Cancer, 1980
E. Farmer, E. B. Helwig
semanticscholar   +1 more source

Delivery of Pleckstrin‐Homology Domains Suppresses PI3K/Akt Signaling and Breast Cancer Metastasis

Advanced Science, EarlyView.
Current therapies curb tumor growth but not metastasis. Obscurin, a giant metastasis suppressor lost in breast cancer, restrains PI3K/Akt signaling but is impractical to restore. We deploy a mini‐obscurin, comprising the obscurin‐PH‐domain, which sequesters PI3K‐p85, potently suppressing invasion and metastasis.
Matthew Eason, Anindya Sen, Suhan Cho, Se Jong Lee, Keyata Thompson, Md Musavvir Mahmud, Poornima Dubey, Talia Guardia, Anthony Kim, Stuart Martin, Nathan Wright, Konstantinos Konstantopoulos, Aikaterini Kontrogianni‐Konstantopoulos   +12 more
wiley   +1 more source

Context‐Dependent Role of GDF15: GDF15+ Tumor‐Associated Macrophages Suppress OSCC Progression by Enhancing Phagocytosis

Advanced Science, EarlyView.
This study identifies GDF15+ TAMs as a cell subset mediating tumor regression after immunotherapy. Macrophage‐intrinsic GDF15 enhances phagocytosis and antigen cross‐presentation to CD8+ T cells through the NF‐κB signaling pathway, thereby inhibiting tumor progression.
Xinyu Zhou, Zhihang Zhou, Houyu Ju, Chaoyang Guo, Fangxing Zhu, Yiyi Zhang, Xu Chen, Tongchao Zhao, Laiping Zhong, Jingzhou Hu   +9 more
wiley   +1 more source

Combination Immunotherapy as a Promising Strategy to Overcome Immunotherapy Resistance: From Emergence to Next‐Generation Approaches

Advanced Science, EarlyView.
This review examines emerging combination immunotherapy strategies tailored to distinct tumor microenvironments and highlights next‐generation biomarkers that guide response prediction and treatment personalization. It integrates lessons from unsuccessful trials, addresses toxicity challenges, and outlines approaches for early biomarker discovery and ...
Asmita Pandey, Sudhir Kumar Rai, Li Ma, Lauren Higa, Vedbar Khadka, Hua Yang, Youping Deng   +6 more
wiley   +1 more source

Immunotherapy for locally advanced and metastatic basal cell carcinoma: a narrative review. [PDF]

Transl Cancer Res
Li X, Wang H, Lu Q.
europepmc   +1 more source

A Dual‐Responsive Versatile Nanohybrid Orchestrating Tumor Elimination and Tumor‐Associated Osteolysis Restoration via Sequential Release

Advanced Science, EarlyView.
The versatile CaO2@CuMOF@HAP nanohybrid demonstrates an outstanding MMP9/pH‐triggered release performance for sequential release of osteogenic growth peptide into deep‐seated tumor‐infiltrated bone destruction areas and dual ions into tumor cells, enabling efficient tumor‐associated osteolysis restoration and tumor elimination for more comprehensive ...
Lan Liu, Han‐Zhe Liu, Zhe‐Nan Liu, Tong Wang, Li‐Li Yu, Qiu‐Jing Li, Zi‐Yi Chen, Guo‐Feng Luo, Zheng‐Jun Shang   +8 more
wiley   +1 more source

Clinical Improvement of Treatment-Resistant Metastatic Basal Cell Carcinoma After Intratumoral Injection of Talimogene Laherparepvec. [PDF]

Dermatol Surg
Che Y, Abou-Taleb F, Reddy SA, Chang ALS.   +3 more
europepmc   +1 more source

Metastatic Basal Cell Carcinoma [PDF]

, 2020
openaire   +1 more source

U.S. Food and Drug Administration Approval: Vismodegib for Recurrent, Locally Advanced, or Metastatic Basal Cell Carcinoma

Clinical Cancer Research, 2013
M. Axelson, Ke Liu, Xiaoping Jiang, Kun He, Jian Wang, Hong Zhao, Dubravka Kufrin, Todd R. Palmby, Z. Dong, A. Russell, S. Miksinski, P. Keegan, R. Pazdur   +12 more
semanticscholar   +1 more source